Autoplaque vs vascuCAP
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a workstation-based solution for precise, quantitative analysis of coronary plaques and luminal stenoses directly from CT angiography images. This tool is ideal for clinicians who require automated yet reviewable and editable segmentation of vessels, plaque, and lumen to accurately assess heart attack risk and guide immediate treatment decisions.
View Autoplaque →Choose vascuCAP if…
Choose vascuCAP if you require a comprehensive, histologically-validated analysis of plaque *composition* across various arterial vessels, beyond just coronary, to stratify risk for both stroke and heart attack. This solution is best suited for clinicians seeking 3D visualization and detailed quantification of plaque components like lipid-rich necrotic core to inform personalized, long-term cardiovascular treatment strategies, with flexible cloud or on-premise deployment.
View vascuCAP →When choosing between Autoplaque and vascuCAP (now ElucidVivo/PlaqueIQ), physicians should consider their primary focus for cardiovascular risk assessment. Autoplaque, developed by Cedars-Sinai AIM, excels in quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. It provides automated vessel, plaque, and lumen segmentation, offering detailed measurements of vessel diameter and area. This tool is best suited for clinicians who prioritize a workstation-based solution for in-depth morphological analysis of coronary anatomy and pathology to aid in heart attack risk prediction and treatment guidance.
In contrast, Elucid Bioimaging’s vascuCAP offers a more comprehensive plaque characterization, quantifying specific plaque components such as lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage. This histologically-validated quantification supports risk stratification for stroke and heart attack, and aids in personalized treatment decisions. The key practical difference lies in vascuCAP’s ability to provide detailed plaque composition analysis, which Autoplaque does not explicitly list as a feature. Physicians seeking a broader understanding of plaque biology and its implications for both coronary and cerebrovascular risk, with flexible cloud or on-premise deployment, may find vascuCAP more aligned with their needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | vascuCAP |
|---|---|---|
| Pricing | Not disclosed | Contact for pricing |
| Deployment | Workstation-based software, runs on Windows or Mac computer platforms | Cloud and on-premise |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
vascuCAPTool B (vascuCAP/ElucidVivo) offers both cloud and on-premise deployment options, providing greater flexibility in access and integration into various clinical environments. Its design emphasizes adherence to typical clinical workflow patterns and robust DICOM/PACS/EMR interoperability, suggesting a more seamless integration into existing hospital systems. Tool A is workstation-based, which may limit its accessibility compared to cloud solutions.
Clinical Value
vascuCAPTool B (vascuCAP/ElucidVivo) demonstrates superior clinical value through its histologically-validated quantification of specific vulnerable plaque components, such as lipid-rich necrotic core and intraplaque hemorrhage, which are critical for advanced risk stratification. It also offers the derivation of fractional flow reserve (FFRct), providing a more comprehensive assessment of lesion-specific ischemia. While Tool A provides quantitative analysis, Tool B's deeper, validated insights into plaque composition and physiology offer a more advanced clinical utility.
Pricing & Value
vascuCAPBoth tools have undisclosed pricing, making a direct cost comparison impossible. However, Tool B (vascuCAP/ElucidVivo/PlaqueIQ) has recently secured broad reimbursement, including a new Category I CPTu00ae designation and widespread coverage from public and private payors, effective January 1, 2026. This indicates a recognized clinical utility and financial viability within the healthcare system, suggesting a higher perceived value despite undisclosed direct pricing.
Enterprise Readiness
vascuCAPTool B (vascuCAP/ElucidVivo) is explicitly HIPAA compliant and offers a Business Associate Agreement (BAA), which are essential for enterprise-level data security and regulatory compliance. Its flexible cloud and on-premise deployment options, coupled with DICOM/PACS/EMR interoperability, ensure seamless integration into diverse IT infrastructures. Tool A, being workstation-based and lacking explicit compliance statements, appears less prepared for large-scale enterprise deployment.
Innovation
vascuCAPTool B (vascuCAP/ElucidVivo) showcases greater innovation by providing histologically-validated quantification of specific vulnerable plaque components and deriving fractional flow reserve (FFRct) from CTA images. Its exploration of 'Virtual Transcriptomics' further pushes the boundaries of non-invasive cardiovascular assessment. While Tool A uses AI for quantitative plaque analysis, Tool B's depth of insight into plaque biology and physiological impact represents a more cutting-edge approach.
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient specific details regarding comprehensive support channels, service level agreements, or extensive publicly available documentation for either tool. Both imply the existence of user manuals and training, but a clear distinction in support offerings cannot be made.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | vascuCAP |
|---|---|---|
| Name | Autoplaque | vascuCAP (now ElucidVivo/PlaqueIQ) |
| Company | Cedars-Sinai Medical Center: AIM | Elucid Bioimaging |
| Tagline | AI-Powered Quantitative Analysis for Coronary Plaque and Stenosis | AI-enabled software for precise cardiovascular diagnostic imaging and plaque assessment. |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque, Detection and characterization of coronary artery plaque, Measurement of luminal stenoses, Analysis of coronary anatomy and pathology from CT Angiographic images, Workstation-based post-processing application, Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician), Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views, Measurement of vessel diameter and area | AI-enabled CT angiogram analysis, Histologically-validated plaque quantification and characterization, 3D visualization of arterial vessels and plaque, Risk stratification for stroke and heart attack, Support for personalized treatment decisions, Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage, DICOM integration and PACS/EMR interoperability, Cloud and on-premise secure deployment options |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and vascuCAP.